对我们覆盖范围的美国临床肿瘤学会（ASCO）摘要的初步解读

M UpdateBiotechnology | North America1st Take on ASCO Abstracts for Our Coverage We provide a first look at key ASCO abstracts for our coverage. For GMAB, initial PhI/II Rina-S EC efficacy is competitive, and we await further context on the Gr5 event. For LEGN, data for Carvykti remain impressive and DLL3 & Claudin 18.2 updates present an intriguing start to the pipeline.Morgan Stanley & Co. LLCVikram PurohitEquity Analyst Vikram.Purohit@morganstanley.com +1 212 761-3804 Parth PatelResearch Associate Parth.Patel@morganstanley.com +1 212 761-5065 Morgan K GrygaResearch Associate Morgan.Gryga@morganstanley.com +1 212 761-0824 BiotechnologyNorth AmericaIndustry ViewAttractiveGenmab (GMAB): Abstract 3039 - Rinatabart sesutecan